{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Munteanu M"],"funding":["Medical Research Council","National Institute for Health Research (NIHR)","Seventh Framework Programme"],"pagination":["877-89"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC5113673"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["44(8)"],"pubmed_abstract":["<h4>Background</h4>Blood tests of liver injury are less well validated in non-alcoholic fatty liver disease (NAFLD) than in patients with chronic viral hepatitis.<h4>Aims</h4>To improve the validation of three blood tests used in NAFLD patients, FibroTest for fibrosis staging, SteatoTest for steatosis grading and ActiTest for inflammation activity grading.<h4>Methods</h4>We pre-included new NAFLD patients with biopsy and blood tests from a single-centre cohort (FibroFrance) and from the multicentre FLIP consortium. Contemporaneous biopsies were blindly assessed using the new steatosis, activity and fibrosis (SAF) score, which provides a reliable and reproducible diagnosis and grading/staging of the three elementary features of NAFLD (steatosis, inflammatory activity) and fibrosis with redu"],"journal":["Alimentary pharmacology & therapeutics"],"pubmed_title":["Diagnostic performance of FibroTest, SteatoTest and ActiTest in patients with NAFLD using the SAF score as histological reference."],"pmcid":["PMC5113673"],"funding_grant_id":["FP7/2007‐2013","CL-2013-01-002","HEALTH‐F2‐2009‐241762","MC_UU_12013/5"],"pubmed_authors":["Sorensen T","Perlemuter G","Mercadier A","Gouw AS","Bellentani S","Castille JM","FLIP Consortium and the FibroFrance Group","Bruckert E","Munteanu M","Rosmorduc O","Varsat B","Marra F","Schirmacher P","Ngo Y","Deckmyn O","Ziol M","Hartemann A","Montani M","De Minicis S","David E","Perazzo H","Losi L","Wendum D","Romero Gomez M","Cabibi D","Trauner M","Giral P","Traussnig S","Bismuth FI","Pareja MJ","Thabut D","Tiniakos D","Lawlor D","Bugianesi E","Ratziu V","Moussalli J","Dufour JF","Wrba F","Poynard T","Langon T","Lebray P","Marchesini G","Burt AD","Anstee Q","Naveau S","Rudler M","Bedossa P","Lackner C","Jacqueminet S","Brain J","Tribelli C","Day C","Bury Y","Terracciano L","Oliveira C","Charlotte F","Calmus Y"],"additional_accession":[]},"is_claimable":false,"name":"Diagnostic performance of FibroTest, SteatoTest and ActiTest in patients with NAFLD using the SAF score as histological reference.","description":"<h4>Background</h4>Blood tests of liver injury are less well validated in non-alcoholic fatty liver disease (NAFLD) than in patients with chronic viral hepatitis.<h4>Aims</h4>To improve the validation of three blood tests used in NAFLD patients, FibroTest for fibrosis staging, SteatoTest for steatosis grading and ActiTest for inflammation activity grading.<h4>Methods</h4>We pre-included new NAFLD patients with biopsy and blood tests from a single-centre cohort (FibroFrance) and from the multicentre FLIP consortium. Contemporaneous biopsies were blindly assessed using the new steatosis, activity and fibrosis (SAF) score, which provides a reliable and reproducible diagnosis and grading/staging of the three elementary features of NAFLD (steatosis, inflammatory activity) and fibrosis with redu","dates":{"release":"2016-01-01T00:00:00Z","publication":"2016 Oct","modification":"2026-05-29T20:29:55.143Z","creation":"2019-03-27T02:29:12Z"},"accession":"S-EPMC5113673","cross_references":{"pubmed":["27549244"],"doi":["10.1111/apt.13770"]}}